Table 1 Baseline characteristics of patients in the training and the validation cohort
All cohort (N = 2021) | Training cohort (N = 1415) | Validation cohort (N = 606) | P value | |
|---|---|---|---|---|
Age | ||||
Median (IQR) | 63 (56–70) | 63 (56–70) | 63 (56–71) | 0.606 |
Year of Diagnosis | ||||
2010 | 344 (17.0%) | 227 (16.0%) | 117 (19.3%) | 0.450 |
2011 | 335 (16.6%) | 234 (16.5%) | 101 (16.7%) | |
2012 | 356 (17.6%) | 261 (18.4%) | 95 (15.7%) | |
2013 | 364 (18.0%) | 255 (18.0%) | 109 (18.0%) | |
2014 | 319 (15.8%) | 227 (16.0%) | 92 (15.2%) | |
2015 | 303 (15.0%) | 211 (14.9%) | 92 (15.2%) | |
Sex | ||||
Male | 1681 (83.2%) | 1177 (83.2%) | 504 (83.2%) | 0.995 |
Female | 340 (16.8%) | 238 (16.8%) | 102 (16.8%) | |
Race | ||||
White | 1521 (75.3%) | 1061 (75.0%) | 460 (75.9%) | 0.906 |
Black | 352 (17.4%) | 249 (17.6%) | 103 (17.0%) | |
Other | 148 (7.3%) | 105 (7.4%) | 43 (7.1%) | |
Grade | ||||
Grade I-II | 853 (42.2%) | 601 (42.5%) | 252 (41.6%) | 0.909 |
Grade III-IV | 687 (34.0%) | 477 (33.7%) | 210 (34.7%) | |
Unknown | 481 (23.8%) | 337 (23.8%) | 144 (23.8%) | |
AJCC Stage | ||||
I | 71 (3.5%) | 44 (3.1%) | 27 (4.5%) | 0.221 |
II | 172 (8.5%) | 118 (8.3%) | 54 (8.9%) | |
III | 357 (17.7%) | 241 (17.0%) | 116 (19.1%) | |
IV | 1421 (70.3%) | 1012 (71.5%) | 409 (67.5%) | |
T stage | ||||
T1 | 194 (9.6%) | 132 (9.3%) | 62 (10.2%) | 0.722 |
T2 | 692 (34.2%) | 491 (34.7%) | 201 (33.2%) | |
T3 | 509 (25.2%) | 349 (24.7%) | 160 (26.4%) | |
T4 | 626 (31.0%) | 443 (31.3%) | 183 (30.2%) | |
N stage | ||||
N0 | 480 (23.8%) | 328 (23.2%) | 152 (25.1%) | 0.561 |
N1 | 380 (18.8%) | 263 (18.6%) | 117 (19.3%) | |
N2 | 1036 (51.3%) | 731 (51.7%) | 305 (50.3%) | |
N3 | 125 (6.2%) | 93 (6.6%) | 32 (5.3%) | |
M stage | ||||
M0 | 1839 (91.0%) | 1280 (90.5%) | 559 (92.2%) | 0.199 |
M1 | 182 (9.0%) | 135 (9.5%) | 47 (7.8%) | |
Treatment | ||||
Surgery | ||||
Yes | 356 (17.6%) | 252 (17.8%) | 104 (17.2%) | 0.726 |
No | 1665 (82.4%) | 1163 (82.2%) | 502 (82.8%) | |
Radiotherapy | ||||
Yes | 1642 (81.2%) | 1148 (81.1%) | 494 (81.5%) | 0.838 |
No | 379 (18.8%) | 267 (18.9%) | 112 (18.5%) | |
Chemotherapy | ||||
Yes | 1434 (71.0%) | 1015 (71.7%) | 419 (69.1%) | 0.240 |
No | 587 (29.0%) | 400 (28.3%) | 187 (30.9%) | |